164 related articles for article (PubMed ID: 23549785)
1. ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines.
Radtke S; Milanovic M; Rossé C; De Rycker M; Lachmann S; Hibbert A; Kermorgant S; Parker PJ
J Cell Sci; 2013 Jun; 126(Pt 11):2381-91. PubMed ID: 23549785
[TBL] [Abstract][Full Text] [Related]
2. PKC mediates fluctuant ERK-paxillin signaling for hepatocyte growth factor-induced migration of hepatoma cell HepG2.
Hu CT; Cheng CC; Pan SM; Wu JR; Wu WS
Cell Signal; 2013 Jun; 25(6):1457-67. PubMed ID: 23524339
[TBL] [Abstract][Full Text] [Related]
3. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion.
Ma PC; Tretiakova MS; Nallasura V; Jagadeeswaran R; Husain AN; Salgia R
Br J Cancer; 2007 Aug; 97(3):368-77. PubMed ID: 17667909
[TBL] [Abstract][Full Text] [Related]
4. GIT1 is a novel MEK1-ERK1/2 scaffold that localizes to focal adhesions.
Zhang N; Cai W; Yin G; Nagel DJ; Berk BC
Cell Biol Int; 2009 Dec; 34(1):41-7. PubMed ID: 19947948
[TBL] [Abstract][Full Text] [Related]
5. MET/ERK2 pathway regulates the motility of human alveolar rhabdomyosarcoma cells.
Otabe O; Kikuchi K; Tsuchiya K; Katsumi Y; Yagyu S; Miyachi M; Iehara T; Hosoi H
Oncol Rep; 2017 Jan; 37(1):98-104. PubMed ID: 27840956
[TBL] [Abstract][Full Text] [Related]
6. Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma.
Tjin EP; Groen RW; Vogelzang I; Derksen PW; Klok MD; Meijer HP; van Eeden S; Pals ST; Spaargaren M
Blood; 2006 Jan; 107(2):760-8. PubMed ID: 16189274
[TBL] [Abstract][Full Text] [Related]
7. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells.
Jagadeeswaran R; Jagadeeswaran S; Bindokas VP; Salgia R
Am J Physiol Lung Cell Mol Physiol; 2007 Jun; 292(6):L1488-94. PubMed ID: 17322284
[TBL] [Abstract][Full Text] [Related]
8. PKCε-mediated c-Met endosomal processing directs fluctuant c-Met-JNK-paxillin signaling for tumor progression of HepG2.
Hu CT; Cheng CC; Wu JR; Pan SM; Wu WS
Cell Signal; 2015 Jul; 27(7):1544-55. PubMed ID: 25778903
[TBL] [Abstract][Full Text] [Related]
9. Erk2 but not Erk1 regulates crosstalk between Met and EGFR in squamous cell carcinoma cell lines.
Gusenbauer S; Zanucco E; Knyazev P; Ullrich A
Mol Cancer; 2015 Mar; 14():54. PubMed ID: 25884419
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte growth factor induces ERK-dependent paxillin phosphorylation and regulates paxillin-focal adhesion kinase association.
Liu ZX; Yu CF; Nickel C; Thomas S; Cantley LG
J Biol Chem; 2002 Mar; 277(12):10452-8. PubMed ID: 11784715
[TBL] [Abstract][Full Text] [Related]
11. Prolonged nuclear retention of activated extracellular signal-regulated kinase 1/2 is required for hepatocyte growth factor-induced cell motility.
Tanimura S; Nomura K; Ozaki K; Tsujimoto M; Kondo T; Kohno M
J Biol Chem; 2002 Aug; 277(31):28256-64. PubMed ID: 12032150
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of hepatocyte growth factor-mediated vascular smooth muscle cell migration.
Ma H; Calderon TM; Kessel T; Ashton AW; Berman JW
Circ Res; 2003 Nov; 93(11):1066-73. PubMed ID: 14576199
[TBL] [Abstract][Full Text] [Related]
14. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
[TBL] [Abstract][Full Text] [Related]
15. c-jun amino-terminal kinase and mitogen activated protein kinase 1/2 mediate hepatocyte growth factor-induced migration of brain endothelial cells.
Rush S; Khan G; Bamisaiye A; Bidwell P; Leaver HA; Rizzo MT
Exp Cell Res; 2007 Jan; 313(1):121-32. PubMed ID: 17055484
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
[TBL] [Abstract][Full Text] [Related]
17. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.
Calles A; Kwiatkowski N; Cammarata BK; Ercan D; Gray NS; Jänne PA
Mol Oncol; 2015 Jan; 9(1):260-9. PubMed ID: 25226813
[TBL] [Abstract][Full Text] [Related]
18. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.
Navab R; Liu J; Seiden-Long I; Shih W; Li M; Bandarchi B; Chen Y; Lau D; Zu YF; Cescon D; Zhu CQ; Organ S; Ibrahimov E; Ohanessian D; Tsao MS
Neoplasia; 2009 Dec; 11(12):1292-300. PubMed ID: 20019837
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells.
You B; Yang YL; Xu Z; Dai Y; Liu S; Mao JH; Tetsu O; Li H; Jablons DM; You L
Oncotarget; 2015 Feb; 6(6):4357-68. PubMed ID: 25738359
[TBL] [Abstract][Full Text] [Related]
20. Matriptase is required for the active form of hepatocyte growth factor induced Met, focal adhesion kinase and protein kinase B activation on neural stem/progenitor cell motility.
Fang JD; Lee SL
Biochim Biophys Acta; 2014 Jul; 1843(7):1285-94. PubMed ID: 24685580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
